None listed
Conditions
Interventions
Colistin combined with Tanreqing group:Colistin and Tanreqing
Colistin group:Aerosol inhalation of colistin
Tanreqing group: Intravenous Tanreqing
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 2 consecutive positive isolation of drug-resistant Pseudomonas aeruginosa in lower respiratory tract specimens(bronchial suction or bronchoscopy sampling) (drug resistance is defined as at least three kinds of antimicrobial resistance for the following drugs: cephalosporin, carbapenems, beta-lactamase inhibitor, fluoroquinolone, aminoglycoside), and clinically diagnosed as multidrug-resistant Pseudomonas aeruginosa colonization; 2. Patients with an artificial airway; 3. Patients requiring bronchoalveolar lavage for diagnosis and treatment; 4. patients with recent lung imaging and blood inflammation index examination results; 5. Informed consent signed by the patient himself or his legal guardian; 6. Patients aged >=18 years and <75 years.
Exclusion criteria
Exclusion criteria: 1. The presence of a lung infection (All the following manifestations are met: (1) New or progressive pulmonary infiltration, consolidation, or ground glass on chest X-ray or CT; (2) Meeting at least two of the following clinical characteristics: body temperature > 38?, peripheral white blood cells > 10x10^9/L or 2 times the upper limit of normal; 6. Using neurotoxic drugs; 7. Severe cor pulmonale with heart failure; 8. TCM syndrome differentiation belongs to the surface cold syndrome; 9. A history of intravenous or atomized inhalation of colistin sulfate within 3 days; 10. Patients requiring systematic treatment with antibacterial agents against Pseudomonas aeruginosa; 11. Patients who are concomitant or expected to use nephrotoxic drugs (e.g. vancomycin and aminoglycosides) during the study period; 12. Extubation is expected within 7 days; 13. Patients who cannot cooperate with atomizing inhalation therapy; 14. Patients who cannot receive bronchoalveolar lavage; 15. Any serious medical condition or mental disorder which, in the opinion of the investigator, may endanger the safety of the patient or interfere with the completion of treatment under this protocol; 16. Pregnant or lactating patients or patients of childbearing age who are trying to conceive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Pseudomonas aeruginosa load in lower respiratory tract specimens cultured within 24 h of the end of last treatment compared to baseline; | — |
Countries
China
Contacts
Public ContactZhang Jing
Outcome results
None listed